Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-SPERANZA COVID Project: montelukast for respiratory symptoms in long COVID
2021-000605-24Phase 3Terminated
- Sponsor
- IDIAPJGol
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in post-COVID syndrome and coronavirus disease 2019 (COVID-19) comparing Montelukast with Placebo (2 arms). Primary endpoint: Quality of life of respiratory symptoms at 4 weeks. Started Jul 2021; status: terminated.
02
Drugs
montelukast
03
Conditions
post-COVID syndromecoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-000605-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000605-24.